Stock on Demand This Week: Lucira Health Inc. (LHDX)

0
5
PTGX
PTGX

Lucira Health Inc. (NASDAQ:LHDX) saw an upside of 0.09% to $0.32 after subtracting $0.0 on Tuesday. The 5-day average trading volume is 5,209,350 shares of the company’s common stock. It has gained $0.4496 in the past week and touched a new high 2 times within the past 5 days. An average of 15,128,718 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 6,264,653.

LHDX’s 1-month performance is 79.34% or $0.1749 on its low of $0.1080 reached on 12/30/22. The company’s shares have touched a 52-week low of $0.11 and high of $5.67, with the stock’s rally to the 52-week high happening on 01/03/23. YTD, LHDX has achieved 192.17% or $0.2038 and has reached a new high 1 time. However, the current price is down -94.27% from the 52-week high price.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Insider Transactions

LHDX stock investors last saw insider trading activity on Dec 20.Allen Anthony Joseph (Chief Operations Officer) most recently sold 4,263 shares at $0.16 per share on Dec 20. This transaction cost the insider $682. Interim CFO, Narido Richard Clavano, sold 1,583 shares at a price of $0.36 on Dec 01. Then, on Nov 28, Ex VP & Chief Quality Officer Kashmolah Ghazi sold 7,537 shares at a price of $0.42 per share. This transaction amounted to $3,166.

Valuation Metrics

Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.05 while the price-to-book (PB) in the most recent quarter is 0.21.

Lucira Health Inc.’s quick ratio for the period ended September 29 was 0.80, with the current ratio over the same period at 1.50. As well, the company’s long term debt to equity for the quarter ending September 29 was 0.48, while the total debt to equity was 0.48. In terms of profitability, the gross margin trailing 12 months is -16.00%. The firm’s gross profit as reported stood at $10.22 million against revenue of $93.06 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected LHDX to announce -$0.38 per share in earnings in its latest quarter, but it posted -$3.15, representing a -728.90% surprise. EBITDA for the quarter stood at more than -$124.36 million. LHDX stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 128.3 million, with total debt at $48.09 million. Shareholders hold equity totaling $40.6 million.

Let’s look briefly at Lucira Health Inc. (LHDX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 51.04% to suggest the stock is trending Neutral, with historical volatility in this time period at 140.23%.

The stock’s 5-day moving average is $0.3027, reflecting a +4.79% or $0.0144 change from its current price. LHDX is currently trading +124.93% above its 20-day SMA, -82.55% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -56.26% and SMA200 by-92.01%.

Stochastic %K and %D was 28.43% and 25.89% and the average true range (ATR) pointed at 0.0849. The RSI (14) points at 49.39%, while the 14-day stochastic is at 30.00% with the period’s ATR at 0.0877. The stock’s 9-day MACD Oscillator is pointing at 0.0114 and -0.0106 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Lucira Health Inc. (NASDAQ: LHDX), William Blair downgraded it to a Mkt perform rating. They previously had an Outperform rating on the stock. Analysts offering their rating for LHDX stock have a consensus rating for the stock as Underweight. Currently, 0 brokerage advisors rate LHDX as a “sell,”, while 1 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.

What is LHDX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $0.50 and a high of $0.50, with their median price target at $0.50. Looking at these predictions, the average price target given by analysts is for Lucira Health Inc. (LHDX) stock is $0.50.

LEAVE A REPLY

Please enter your comment!
Please enter your name here